Research progress on traditional Chinese medicine regulating NLRP3 inflammasome to alleviate doxorubicin toxicity
LIN Xinying, LI Jialu, LUO Hengsen, SHUAI Yangyang, PENG Cheng, XIE Xiaofang
Affiliations
doi: 10.7501/j.issn.0253-2670.2026.10.029
文章导航
摘要
收起
阿霉素是临床广泛应用的蒽环类抗肿瘤药物，但治疗价值因其具有剂量相关性心脏毒性、肾毒性等不良反应受到显著制约，亟需寻找防治药物。近年的研究发现，NOD样受体热蛋白结构域3（NOD like receptor family pyrin domain containing 3，NLRP3）的异常激活是阿霉素诱导不同靶器官毒性的重要环节之一，而中药及其有效成分能够有效抑制NLRP3炎性小体而减轻阿霉素引起的毒性。通过系统总结近年来中药及活性成分通过调控NLRP3炎症小体改善阿霉素毒性的实验研究进展，发现其心脏、肾脏、肝保护等方面均可缓解阿霉素毒性，为中药干预阿霉素的相关毒副作用提供了重要的理论依据和潜在治疗策略。
关键词
阿霉素毒性
/
NOD样受体热蛋白结构域3
/
中药
/
心脏毒性
/
肾毒性
/
肝毒性
Abstract
收起
Doxorubicin is an anthracycline antitumor drug widely used in clinical practice, but its therapeutic value is significantly limited due to adverse reactions such as dose-dependent cardiotoxicity and nephrotoxicity, and there is an urgent need to find preventive and therapeutic drugs. Recent studies have found that abnormal activation of NOD-like receptor family pyrin domain containing 3 (NLRP3) is one of the important mechanisms underlying doxorubicin-induced toxicity in different target organs, whereas traditional Chinese medicine (TCM) and its active components can effectively inhibit the NLRP3 inflammasome and alleviate doxorubicin-induced toxicity. By systematically summarizing recent experimental research on how TCM and its active components ameliorate doxorubicin toxicity through regulating the NLRP3 inflammasome, it was found that they can alleviate doxorubicin toxicity in terms of cardiac and renal protection. These studies provide important theoretical evidence and potential therapeutic strategies for using TCM to intervene in the related adverse effects of doxorubicin.
Key words
doxorubicin toxicity
/
NOD-like receptor family pyrin domain containing 3
/
traditional Chinese medicine
/
cardiotoxicity
/
nephrotoxicity
/
hepatotoxicity
LIN Xinying, LI Jialu, LUO Hengsen, SHUAI Yangyang, PENG Cheng, XIE Xiaofang.
Research progress on traditional Chinese medicine regulating NLRP3 inflammasome to alleviate doxorubicin toxicity[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(10)
: 4017
-4027
.
DOI: 10.7501/j.issn.0253-2670.2026.10.029
张淼, 谭楠楠, 姜泽丰, 等. 中药防治阿霉素心脏毒性的机制研究进展[J]. 中华老年心脑血管病杂志, 2023, 25(3): 322-324. Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin [J]. Life Sci, 2021, 278: 119527. Pugazhendhi A, Edison T N J I, Velmurugan B K, et al. Toxicity of doxorubicin (Dox) to different experimental organ systems [J]. Life Sci, 2018, 200: 26-30. 贺升升, 李爱平, 张王宁, 等. 阿霉素肾病模型及其病理机制研究进展[J]. 中草药, 2018, 49(22): 5426-5434. Rawat P S, Jaiswal A, Khurana A, et al. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management [J]. Biomed Pharmacother, 2021, 139: 111708. Kabel A M. Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling [J]. Biomed Pharmacother, 2018, 97: 439-449. Zahid A, Li B F, Kombe A J K, et al. Pharmacological inhibitors of the NLRP3 inflammasome [J]. Front Immunol, 2019, 10: 2538. 刘双慧, 张衍坤, 赵毅, 等. 基于NLRP3/Caspase-1/ GSDMD通路探讨木犀草素对LPS/ATP诱导的细胞焦亡的保护机制[J]. 中草药, 2025, 56(6): 1989-1998. Coll R C, Schroder K. Inflammasome components as new therapeutic targets in inflammatory disease [J]. Nat Rev Immunol, 2025, 25(1): 22-41. 梁国庆, 夏冉, 王银燕, 等. 基于NLRP3/Caspase-1信号通路探讨参芪健心方对慢性心力衰竭模型大鼠心肌细胞焦亡的影响[J]. 中医杂志, 2024, 65(1): 94-102. 张书文, 崔佳乐, 邱春辉, 等. 基于NLRP3/Caspase-1/ GSDMD通路探讨阿霉素纳米凝胶载药对H22肝癌荷瘤小鼠的作用机制[J]. 中国实验诊断学, 2025, 29(1): 74-78. 邹翔, 孙雨恒, 刘凯丽, 等. 白屈菜碱-延胡索乙素联合阿霉素通过NLRP3/Caspase-1途径协同诱导人乳腺癌MCF-7/ADR细胞焦亡作用机制[J]. 中草药, 2025, 56(4): 1234-1243. Chen Y, Xu M, Liu X M, et al. Mechanistic study of Huangqi Guizhi Wuwu Decoction amelioration of doxorubicin-induced cardiotoxicity by reducing oxidative stress and inhibiting cellular pyroptosis [J]. Biomed Pharmacother, 2024, 175: 116653. Hao W, Shi Y Y, Qin Y N, et al. Cardioprotective effect of Chinese herbal medicine for anthracycline-induced cardiotoxicity in cancer patients: A Meta-analysis of prospective studies [J]. Medicine, 2022, 101(30): e29691. Wan P, Zhang Q, Liu W Y, et al. Cullin1 binds and promotes NLRP3 ubiquitination to repress systematic inflammasome activation [J]. FASEB J, 2019, 33(4): 5793-5807. Kodi T, Sankhe R, Gopinathan A, et al. New insights on NLRP3 inflammasome: Mechanisms of activation, inhibition, and epigenetic regulation [J]. J Neuroimmune Pharmacol, 2024, 19(1): 7. Mangan M S J, Olhava E J, Roush W R, et al. Targeting the NLRP3 inflammasome in inflammatory diseases [J]. Nat Rev Drug Discov, 2018, 17(9): 688. 梁甜, 周琳, 周晓玲. NLRP3炎症小体介导的肝纤维化炎症反应及激活机制研究进展[J]. 临床与实验病理学杂志, 2024, 40(6): 636-639. 胡靖, 刘悦, 赵彬, 等. NLRP3炎症小体在早发性卵巢功能不全中的作用及中药单体、提取物、复方及中医干预研究进展[J]. 中药药理与临床, 2026, 42(1): 133-141. 崔馨予, 康惠琴, 贺佩鑫, 等. 中医药干预NOD样受体蛋白3炎症小体治疗类风湿关节炎的研究进展[J]. 时珍国医国药, 2025, 36(7): 1321-1330. Takahashi M. Role of NLRP3 inflammasome in cardiac inflammation and remodeling after myocardial infarction [J]. Biol Pharm Bull, 2019, 42(4): 518-523. Dinarello C A. How interleukin-1β induces gouty arthritis [J]. Arthritis Rheum, 2010, 62(11): 3140-3144. Zhan X Y, Li Q, Xu G, et al. The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors [J]. Front Immunol, 2023, 13: 1109938. Katsnelson M A, Rucker L G, Russo H M, et al. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling [J]. J Immunol, 2015, 194(8): 3937-3952. Zou G L, Tang Y L, Yang J, et al. Signal-induced NLRP3 phase separation initiates inflammasome activation [J]. Cell Res, 2025, 35(6): 437-452. Boršić E, Ramuta T Ž, Orehek S, et al. Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly [J]. Nat Commun, 2025, 16: 4887. 王天宝. 迷迭香酸缓解丙烯酰胺诱导的小鼠神经毒性及其内在机制[D]. 南宁: 广西大学, 2025. 罗子欣. 川芎嗪通过上调AMPKα1并激活细胞自噬抑制细胞焦亡以减轻顺铂肾毒性[D]. 南昌: 南昌大学, 2024. 袁欣颖. NLRP3通过调控肝细胞焦亡在对乙酰氨基酚所致小鼠急性肝损伤的作用研究[D]. 青岛: 青岛大学, 2024. Zhang J P, Cui L J, Han X, et al. Protective effects of tannic acid on acute doxorubicin-induced cardiotoxicity: Involvement of suppression in oxidative stress, inflammation, and apoptosis [J]. Biomed Pharmacother, 2017, 93: 1253-1260. Chen T, Shen H M, Deng Z Y, et al. A herbal formula, SYKT, reverses doxorubicin-induced myelosuppression and cardiotoxicity by inhibiting ROS-mediated apoptosis [J]. Mol Med Rep, 2017, 15(4): 2057-2066. Wei S S, Ma W J, Jiang C H, et al. Hyperoside prevents doxorubicin-induced cardiotoxicity by inhibiting NOXs/ ROS/NLRP3 inflammasome signaling pathway [J]. Phytother Res, 2023, 37(9): 4196-4209. Zhang W, Shi C, Yao Z Y, et al. Bardoxolone methyl attenuates doxorubicin-induced cardiotoxicity by inhibiting the TXNIP-NLRP3 pathway through Nrf2 activation [J]. Environ Toxicol, 2024, 39(4): 1936-1950. 刘东华, 李姿儒, 李思静, 等. 暖心康调控NLRP3/ DAMPs信号通路抑制中性粒细胞胞外陷阱网改善阿霉素心肌损伤的作用及机制[J]. 中国实验方剂学杂志, 2025, 31(23): 40-50. Sun Z Z, Fang C F, Xu S S, et al. SIRT3 attenuates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome via autophagy [J]. Biochem Pharmacol, 2023, 207: 115354. Yin J S, You Y Y, Mao J C, et al. NLRP3 inflammasome regulates doxorubicin-induced cardiotoxicity by modulating the abundance of gut microbiota [J]. Toxicol Appl Pharmacol, 2025, 502: 117455. Kim D R, Lee S Y, Kim J S, et al. Ameliorating effect of gemigliptin on renal injury in murine adriamycin-induced nephropathy [J]. Biomed Res Int, 2017, 2017: 7275109. 梁国强, 倪道磊, 周岚, 等. 基于线粒体自噬途径探讨黄芪甲苷对阿霉素肾病大鼠的肾保护作用[J]. 中华中医药学刊, 2022, 40(9): 35-39. 郑鹏飞. 真武汤对慢性肾脏病肾阳虚证大鼠肾脏保护及HIF-1α/NLRP3/GSDMD通路影响的研究[D]. 北京: 北京中医药大学, 2023. 李蔚. 黄蜀葵花制剂调控ERK1/2-NLRP3炎症小体保护肾小管上皮细胞机理研究[D]. 南京: 南京中医药大学, 2019. Prasanna P L, Renu K, Valsala Gopalakrishnan A. New molecular and biochemical insights of doxorubicin-induced hepatotoxicity [J]. Life Sci, 2020, 250: 117599. El-Dessouki A M, Yousef E H, Raslan N A, et al. Febuxostat protects from doxorubicin induced hepatotoxicity in rats via regulation of NF-κB p65/NLRP3 inflammasome and SIRT-1/AMPK pathways [J]. Naunyn Schmiedebergs Arch Pharmacol, 2025, 398(8): 10125-10137. Tan S Q, Bai J, Xu M X, et al. Thioredoxin-1 activation by pterostilbene protects against doxorubicin-induced hepatotoxicity via inhibiting the NLRP3 inflammasome [J]. Front Pharmacol, 2022, 13: 841330. Zhu M X, Chen Y B, Cheng L T, et al. Calsyntenin-1 promotes doxorubicin-induced dilated cardiomyopathy in rats [J]. Cardiovasc Drugs Ther, 2024, 38(2): 237-252. 班纪芳, 王卓溪, 燕春裕, 等. 中药有效成分调控阿霉素心脏毒性相关信号通路的研究进展[J]. 现代中西医结合杂志, 2025, 34(5): 708-714. 施佳君, 杨钦钦, 富丹婷, 等. 冠心宁片抑制NLRP3/ ASC/Caspase-1通路改善阿霉素诱导的扩张型心肌病大鼠心肌细胞焦亡[J]. 中国实验动物学报, 2024, 32(3): 337-346. 王芳婷. 基于NLRP3/Caspase-1通路探讨强心安神方对CHF大鼠的保护作用机制[D]. 长沙: 湖南中医药大学, 2022. 杨亚利. 基于cGAS/STING信号通路研究苓桂术甘汤抑制心肌细胞焦亡防治阿霉素心脏毒性的作用机制[D]. 合肥: 安徽中医药大学, 2024. 张蕾. 基于NLRP3炎症小体介导的心肌细胞焦亡探讨复心汤对慢性心力衰竭的作用及机制研究[D]. 济南: 山东中医药大学, 2022. Chen Y, Xu M, Liu X M, et al. Mechanistic study of Huangqi Guizhi Wuwu Decoction amelioration of doxorubicin-induced cardiotoxicity by reducing oxidative stress and inhibiting cellular pyroptosis [J]. Biomed Pharmacother, 2024, 175: 116653. 夏晓培, 马广礼, 赵静, 等. 玉米多糖对阿霉素诱导心肌炎症损伤的改善作用及机制研究[J]. 中国食品添加剂, 2024, 35(10): 172-178. Xiong F, Pu L, Wang D B, et al. Investigation of polysaccharide from RadixAconiti Lateralis Preparata (Fuzi) cardio protective effect on doxorubicin-induced chronic cardiotoxicity [J]. J Pharm Pharmacol, 2024, 76(4): 391-404. Zhang X Y, Wang L F, Peng L Z, et al. Dihydromyricetin protects HUVECs of oxidative damage induced by sodium nitroprusside through activating PI3K/Akt/FoxO3a signalling pathway [J]. J Cell Mol Med, 2019, 23(7): 4829-4838. Sun Y, Liu S S, Yang S W, et al. Mechanism of dihydromyricetin on inflammatory diseases [J]. Front Pharmacol, 2022, 12: 794563. Sun Z Z, Lu W Q, Lin N, et al. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1[J]. Biochem Pharmacol, 2020, 175: 113888. Zou H, Zhang M Y, Yang X, et al. Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis [J]. J Zhejiang Univ Sci B, 2024, 25(9): 756-772. 熊凤梅, 刘瑞萍, 李洋, 等. 和厚朴酚可体外减轻阿霉素诱导的心肌毒性: 基于激活AMPK/Nrf2信号通路抑制细胞焦亡[J]. 南方医科大学学报, 2022, 42(8): 1205-1211. Huang P P, Fu J, Liu L H, et al. Honokiol antagonizes doxorubicin-induced cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3 inflammasome activation [J]. Int J Mol Med, 2020, 45(1): 186-194. 陈学恒. 黄芪甲苷通过激活Nrf-2/HO-1通路抑制NLRP3炎症小体介导的焦亡减轻阿霉素诱导的心功能障碍[D]. 济宁: 济宁医学院, 2023. 孟润祺. 黄芪甲苷通过抑制NLRP3炎症小体介导的焦亡保护阿霉素诱导的心肌细胞损伤作用及其机制研究[D]. 济宁: 济宁医学院, 2023. Hu S, Liu B L, Yang M Q, et al. Carnosic acid protects against doxorubicin-induced cardiotoxicity through enhancing the Nrf2/HO-1 pathway [J]. Food Funct, 2023, 14(8): 3849-3862. 郭珊珊, 贾享, 贺武斌, 等. 科罗索酸抑制NLRP3介导的细胞焦亡减轻阿霉素诱导的心肌细胞损伤[J]. 中药药理与临床, 2025, 41(3): 48-53. Deng M, Xie L, Zhong L, et al. Imperatorin: A review of its pharmacology, toxicity and pharmacokinetics [J]. Eur J Pharmacol, 2020, 879: 173124. Zhang H, Ding X Y, Qiu Y M, et al. Preventive effect of imperatorin against doxorubicin-induced cardiotoxicity through suppression of NLRP3 inflammasome activation [J]. J Nat Med, 2025, 79(1): 95-106. 孙嘉. 藁本内酯对阿霉素所致心肌损伤的保护作用[D]. 广州: 广东药科大学, 2022. 蓝永锋, 刘冰, 曾诚. 丁苯肽对阿霉素诱导心肌损伤的保护作用[J]. 广东药科大学学报, 2022, 38(1): 90-96. Maayah Z H, Alam A S, Takahara S, et al. Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice [J]. FEBS Lett, 2021, 595(12): 1681-1695. 王玲娥. 姜黄素对阿霉素心脏毒性小鼠的保护作用[D]. 咸宁: 湖北科技学院, 2021. 陈鹏, 刘石琳, 朱小蕾, 等. 基于FGF2表达探讨红景天苷对阿霉素诱导的心脏毒性的保护作用及对NLRP3炎症小体的影响[J]. 现代中西医结合杂志, 2024, 33(13): 1794-1800. Shackebaei D, Yari K, Rahimi N, et al. Targeting the NLRP3 by natural compounds: Therapeutic strategies to mitigate doxorubicin-induced cardiotoxicity [J]. Cell Biochem Biophys, 2025, 83(3): 2779-2791. Zhao X P, Duan L, Zhao Q R, et al. NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: Role of phytochemicals [J]. Front Pharmacol, 2025, 16: 1567312. 李吉镇. 小檗碱对阿霉素肾病大鼠的肾脏保护作用及机制研究[D]. 济宁: 济宁医学院, 2021. Li G B, Kidd J, Li P L. Podocyte lysosome dysfunction in chronic glomerular diseases [J]. Int J Mol Sci, 2020, 21(5): 1559. Ma Q, Xu M Y, Jing X, et al. Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis [J]. Cell Death Dis, 2023, 14(3): 174. 李昱熹. 糖肾方通过调节足细胞程序性死亡减轻阿霉素肾损伤[D]. 唐山: 华北理工大学, 2024. 刘慧丹, 宋纯东, 宋丹, 等. 基于NLRP3/Caspase-1/IL-1β炎症通路探讨越婢汤和真武汤对阿霉素肾病大鼠的影响[J]. 中国中医基础医学杂志, 2022, 28(3): 357-361. 王嘉文, 屈凯, 詹华奎, 等. 补肾活血祛风复方对阿霉素肾病大鼠肾组织NLRP3水平的干预研究[J]. 四川中医, 2023, 41(6): 59-62. 李蔚, 孙伟, 高坤, 等. 黄葵总黄酮抑制ROS-NLRP3信号转导减轻阿霉素肾损伤[A] // 中国中西医结合学会肾脏疾病专业委员会2018年学术年会论文摘要汇编[C]. 重庆: 中国中西医结合学会肾脏疾病专业委员会2018年学术年会, 2018: 359. 张宇涵, 徐瑞齐, 曾梦楠, 等. 麻黄拆分组分对风水水肿大鼠的干预机制研究[J]. 中药材, 2023, 46(6): 1507-1512. Wu Q J, Li W, Zhao J, et al. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation [J]. Biomed Pharmacother, 2021, 137: 111308. 张之琦. 紫檀芪对阿霉素诱导肾脏损伤的保护作用研究[D]. 沈阳: 沈阳农业大学, 2023. Patel D, Yadav P, Singh S K, et al. Betaine alleviates doxorubicin-induced nephrotoxicity by preventing oxidative insults, inflammation, and fibrosis through the modulation of Nrf2/HO-1/NLRP3 and TGF-β expression [J]. J Biochem Mol Toxicol, 2024, 38(1): e23559. Tian X, Huang Y, Zhang X F, et al. Salidroside attenuates myocardial ischemia/reperfusion injury via AMPK-induced suppression of endoplasmic reticulum stress and mitochondrial fission [J]. Toxicol Appl Pharmacol, 2022, 448: 116093. Wang N, Gao Z S, Zhan H H, et al. Salidroside alleviates doxorubicin-induced hepatotoxicity via Sestrin2/AMPK-mediated pyroptotic inhibition [J]. Food Chem Toxicol, 2025, 199: 115335. 张俐涵. 紫檀芪对阿霉素诱导肝损伤的保护作用研究[D]. 沈阳: 沈阳农业大学, 2023. Mattioli R, Ilari A, Colotti B, et al. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming [J]. Mol Aspects Med, 2023, 93: 101205. Maayah Z H, Takahara S, Dyck J R B. The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin [J]. Arch Toxicol, 2021, 95(1): 1-9. 卞娇娇. DNAJB4增强乳腺癌对阿霉素的敏感性作用及其机制研究[D]. 南充: 川北医学院, 2023.
PDF下载
全屏
25
8
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
